CalciMedica Inc (CALC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.17-1.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
CalciMedica aims to keep enough cash through Q4 2026. Net income rose from negative $10.8 million to positive $5.0 million in early 2026. Diluted EPS improved from negative $0.52 to positive $0.30. The company is advancing clinical trials for its drug Auxora.
CalciMedica is still loss-making with negative EPS expected in coming quarters. The company faces risks from capital needs and regulatory hurdles. Its clinical progress is uncertain and may delay value creation.
The market prices in a weak outlook with negative EPS and no revenue growth. Our fair value is about $6.33, reflecting a turnaround risk. We see potential if cash sufficiency and clinical progress improve.
Breaks if: Cash falls short of funding operations through Q4 2026
Maintain sufficient cash, cash equivalents, and short-term investments to fund current operating plan through Q4 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. CALC is currently navigating a volatile management landscape and is loss-making, which adds to its risk profile.
The market appears to have low expectations for CALC, as indicated by its low fragility tier. However, the recent earnings miss suggests that there may be some fragility in investor sentiment.
Management is focused on advancing clinical development and ensuring cash sufficiency, which shows some positive momentum. However, the company faces an elevated risk of missing earnings in the near term due to its smaller size and erratic performance.
The future of CALC depends on several factors, including the performance of sector bellwethers and the company's ability to meet its clinical development milestones. Additionally, any cuts to guidance could negatively impact investor confidence.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The stock gained 6% due to progress in pulmonary hypertension. However, the company reported a GAAP EPS miss of -$0.45, indicating challenges in improving net income.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No FDA feedback by Q3 2026 or trial delays beyond mid-2027
Breaks if: Diluted EPS remains negative through 2026-Q4
Focus on improving net income and earnings per share performance over recent quarters.
Over the next 1 to 3 years, CALC's performance will largely depend on its execution of management priorities and the broader healthcare sector trends. Not investment advice.